Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
05/19/20178:13AMBWEuropean Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Mye...
Proposal extends application to the treatment of children and adolescents with chronic phase Philadelphia-chromosome positive chronic myelogenous leukemia and to the powder for oral suspension Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its grouped Type II... More...>>
05/17/20175:00PMBWBristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program & Commitment to Exploring Novel Combi...
BMS compounds to be featured in more than 80 presentations spanning 20 types of cancer, with focus on research of precision therapies aimed at improving standards of care First efficacy data for investigational anti-LAG-3 in combination with Opdivo in anti-PD-1/PD-L1 relapsed or refractory patients and for Opdivo in combination... More...>>
05/16/20176:59AMBWBristol-Myers Squibb to Take Part in UBS Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will take part in the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York. Murdo Gordon, executive vice president, head of Commercial, will answer questions about the company at 10 a.m. EDT. Investors and the general public are invited to listen to a live webcast... More...>>
05/10/20176:59AMGLOBEBristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 ...
Study to evaluate potential of CB-839 plus Opdivo to target immunosuppressive cancer metabolism in the tumor microenvironmentCompanies have ongoing collaboration evaluating clear cell renal cell carcinoma NEW YORK and SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE:BMY... More...>>
05/10/20176:59AMBWBristol-Myers Squibb & Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 in...
Study to evaluate potential of CB-839 plus Opdivo to target immunosuppressive cancer metabolism in the tumor microenvironment Companies have ongoing collaboration evaluating clear cell renal cell carcinoma Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage biotechnology... More...>>
05/01/20173:02AMDJNHepatitis C Therapy Approved in China -- WSJ
All-oral Bristol-Myers treatment combines two drugs BEIJING -- China's drug regulator approved Bristol-Myers Squibb Co.'s all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country, giving the U.S. company a leg up in the Chinese market. Friday's... More...>>
04/28/20172:38PMBWEuropean Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head & Neck in Adult...
Opdivo is the first and only Immuno-Oncology agent to receive European approval for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy Opdivo is now approved by the EC for seven indications in five distinct tumor types This is the first approval in Europe... More...>>
04/28/201712:13PMDJNChina Approves Bristol-Myers Dual-Drug Hepatitis C Treatment -- Update
BEIJING -- China's drug regulator approved Bristol-Myers Squibb Co.'s all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country, giving the U.S. company a leg up in the Chinese market. Friday's decision by the China Food and Drug Administration... More...>>
04/28/20178:51AMDJNChina Approves Bristol-Myers Squibb's Dual-Drug Hepatitis C Treatment
BEIJING--China's drug regulator approved Bristol-Myers Squibb Co.'s all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country, giving the U.S. company a leg up in the Chinese market. Friday's decision by the China Food and Drug Administration... More...>>
04/28/20177:19AMBWChina FDA Approves Country’s First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with S...
Daklinza and Sunvepra combination approved for genotype 1b, the most common chronic hepatitis C (HCV) genotype in China; combination has a 91-99% cure rate Daklinza also approved in China for use in combination with other agents, including sofosbuvir, for HCV genotypes 1-6 Bristol-Myers Squibb Company (NYSE:BMY) announced... More...>>
04/27/20178:00AMBWBristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017, in Boston. Charles Bancroft executive vice president, head of Global Business Operations, will answer questions about the company at 11:20 a.m. EDT. Investors and the general public are... More...>>
04/27/20176:59AMBWBristol-Myers Squibb Reports First Quarter Financial Results
Increases First Quarter Revenues 12% to $4.9 Billion Posts First Quarter GAAP EPS of $0.94 and Non-GAAP EPS of $0.84 Achieves Key Regulatory Milestones For Opdivo in the U.S. and Europe Advances Immuno-Oncology Collaborations with Incyte and Exelixis to include Phase 3 Trials Increases 2017 GAAP and Non-GAAP EPS Guidance... More...>>
04/25/20171:30AMBWTransgene & Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo & Sta...
Bristol-Myers Squibb Company (NYSE:BMY) and Transgene today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line... More...>>
04/25/20171:30AMBWTransgene et Bristol-Myers Squibb collaborent à un essai clinique de TG4010 associé avec Opdivo et une chimiothérapie stan...
Regulatory News : Bristol-Myers Squibb Company (NYSE: BMY) et Transgene (Paris:TNG) annoncent la signature d’un accord de collaboration pour la conduite d’une étude clinique visant à évaluer la tolérance et l’efficacité du candidat vaccin thérapeutique TG4010 associé à Opdivo (nivolumab) de Bristol-Myers... More...>>
04/22/20171:01AMBWBristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury & Fibrosis in P...
Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with BMS-986036 Bristol-Myers Squibb Company (NYSE:BMY) today announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism... More...>>
04/21/20172:06PMBWBristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients...
First positive CHMP opinion for an Immuno-Oncology agent for patients with locally advanced or metastatic urothelial cancer CHMP opinion based on tumor response rate and duration of response demonstrated in Phase 2 CheckMate -275 trial Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal... More...>>
04/17/20176:59AMBWBristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology
Collaboration to develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis (NASH) Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially... More...>>
04/13/20177:00AMBWBiogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
Company Sees Potential in Development of BMS-986168 in both Alzheimer’s Disease and Progressive Supranuclear Palsy Biogen Will Pay $300 Million Upfront Plus Potential Milestone Payments and Royalties Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine... More...>>
04/13/20176:59AMBWBristol-Myers Squibb Enters into Separate Agreements with Biogen & Roche to License Anti-eTau & Anti-Myostatin Compounds, Res...
Bristol-Myers Squibb to receive a combined $470M upfront, along with potential milestone payments and tiered double-digit royalties from each company Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for... More...>>
04/11/20176:59AMBWBristol-Myers Squibb & Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX0...
Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumor microenvironment to demonstrate enhanced anti-tumor activity Study to enroll second-line metastatic non-small cell lung cancer (NSCLC) patients who have failed prior chemotherapy and metastatic melanoma patients who have... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20170522 23:08:21